Evidence map›Paper›PMID 39659792›Full record

ArticleFrontiers in oncology2024

Case report: Successful use of ruxolitinib to treat interstitial pneumonia as an unusual primary presentation in primary myelofibrosis-two birds with one stone.

Pingping Xiao, Zhigao Dong, Qingqing Wang, Junnan Su, Yongquan Chen, Yiwan Lin

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pingping XiaoDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Zhigao DongDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Qingqing WangDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Junnan SuDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Yongquan ChenDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Yiwan LinDepartment of Hematology and Rheumatology, The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interstitial lung disease (ILD) is a rare clinical presentation of primary myelofibrosis (PMF). Case presentation: We report a case of ILD as the main manifestation on admission. A 58-year-old man was diagnosed with PMF owing to worsening anemia following treatment failure for conventional interstitial pneumonia. Results: Anemia and interstitial pneumonia both significantly improved following treatment with a Janus kinase 2 gene inhibitor. In this report, we discuss the possible mechanisms underlying PMF complicated with ILD.

Indexed as

interstitial pneumoniaJanus kinase 2primary myelofibrosisruxolitinibten-eleven translocation 2

Identifiers

PMID39659792
PMCPMC11628499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.